Cart
sales@molnova.com
XL228
CAS No. 898280-07-4
XL228( —— )
Catalog No. M24922 CAS No. 898280-07-4
XL228 is an inhibitor of multi-targeted tyrosine kinase.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 64 | In Stock |
|
| 5MG | 91 | In Stock |
|
| 10MG | 137 | In Stock |
|
| 25MG | 244 | In Stock |
|
| 50MG | 372 | In Stock |
|
| 100MG | 552 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameXL228
-
NoteResearch use only, not for human use.
-
Brief DescriptionXL228 is an inhibitor of multi-targeted tyrosine kinase.
-
DescriptionXL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcr-Abl
-
RecptorAurora A|Bcr-Abl|IGF-1R|Lyn|Src
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number898280-07-4
-
Formula Weight437.54
-
Molecular FormulaC22H31N9O
-
Purity>98% (HPLC)
-
SolubilityDMSO:83.33 mg/mL (190.45 mM)
-
SMILESCC(C)c1noc(CNc2nc(N3CCN(C)CC3)cc(Nc3n[nH]c(C4CC4)c3)n2)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Cortes J, et al. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. Blood 2008 112:3232
molnova catalog
related products
-
Vodobatinib
Vodobatinib is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
-
PPY A
PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinase (IC50 of 9 and 20 nM, respectively).PPY A also inhibits the growth of Bcr-Abl T315l mutant or wild-type Bcr-Abl genetically transformed cells.
-
Ponatinib
Ponatinib (AP 24534) is a potent, orally active pan-inhibitor of BCR-ABL kinase with IC50 of 0.37 and 2.0 nM for ABL and mutant ABLT315I, respectively.
